Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COMy Virtual 2020 | Irene Ghobrial: PROMISE

Irene Ghobrial • 28 Apr 2020
COMy Virtual 2020
Multiple Myeloma Rare Diseases Smoldering Myeloma

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the PROMISE study (NCT03689595), which is investigating the screening of individuals at high-risk of progression to multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Irene Ghobrial

The latest updates in the pre-malignant space: the PROMISE study and the potential of immunotherapy
0:57
The latest updates in the pre-malignant space: the PROMISE study and the potential of immunotherapy
Irene Ghobrial • 6 Dec 2025
Results of the PROMISE study of ~30,000 individuals screened for monoclonal gammopathies
1:59
Results of the PROMISE study of ~30,000 individuals screened for monoclonal gammopathies
Irene Ghobrial • 6 Dec 2025
MGIP as a stable premalignant entity preceding hematologic malignancy
2:23
MGIP as a stable premalignant entity preceding hematologic malignancy
Irene Ghobrial • 6 Dec 2025
Risk stratification in smoldering myeloma: current standards and emerging advances
1:05
Risk stratification in smoldering myeloma: current standards and emerging advances
Irene Ghobrial • 17 Sep 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Irene Ghobrial • 18 Dec 2025
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Irene Ghobrial • 7 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Irene Ghobrial • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Irene Ghobrial • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals